¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"macrophage activation factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • photochemical activation
    ±¤È­ÇÐȰ¼ºÈ­
  • sleep activation
    ¼ö¸éȰ¼ºÈ­
  • ventricular activation
    ½É½ÇȰ¼ºÈ­
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • alveolar macrophage
    ÇãÆÄ²Ê¸®Å«Æ÷½Ä¼¼Æ÷, ÆóÆ÷´ë½Ä¼¼Æ÷
  • fixed macrophage
    °íÁ¤Å«Æ÷½Ä¼¼Æ÷, °íÁ¤´ë½Ä¼¼Æ÷
  • foamy macrophage
    Æ÷¸»Å«Æ÷½Ä¼¼Æ÷, °Åǰ´ë½Ä¼¼Æ÷
  • free macrophage
    ÀÚÀ¯Å«Æ÷½Ä¼¼Æ÷, À¯¸®´ë½Ä¼¼Æ÷
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ÜÇÙ±¸´ë½Ä¼¼Æ÷°èÅë
  • macrophage
    Å«Æ÷½Ä¼¼Æ÷, ´ë½Ä¼¼Æ÷
  • macrophage system
    Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ë½Ä¼¼Æ÷°è
  • resident macrophage
    »óÁÖÅ«Æ÷½Ä¼¼Æ÷, »óÁÖ´ë½Ä¼¼Æ÷
  • antihemophilic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement activation
    µµ¿òüȰ¼º, º¸Ã¼È°¼º
  • photochemical activation
    ±¤È­ÇÐȰ¼ºÈ­
  • sleep activation
    ¼ö¸éȰ¼º
  • ventricular activation
    ½É½ÇÈïºÐ
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • alveolar macrophage
    ²Ê¸®Å«Æ÷½Ä¼¼Æ÷, ÆóÆ÷´ë½Ä¼¼Æ÷
  • dendritic macrophage
    °¡Áöµ¹±âÅ«Æ÷½Ä¼¼Æ÷
  • fixed macrophage
    °íÁ¤Å«Æ÷½Ä¼¼Æ÷
  • foamy macrophage
    Æ÷¸»Å«Æ÷½Ä¼¼Æ÷
  • free macrophage
    ÀÚÀ¯Å«Æ÷½Ä¼¼Æ÷
  • macrophage
    Å«Æ÷½Ä¼¼Æ÷, ´ë½Ä¼¼Æ÷
  • macrophage system
    Å«Æ÷½Ä¼¼Æ÷°èÅë
  • macrophage migration test
    Å«Æ÷½Ä¼¼Æ÷À̵¿°Ë»ç
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë
  • resident macrophage
    Åä¹ÚÀÌÅ«Æ÷½Ä¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activation energy
    Ȱ¼ºÈ­¿¡³ÊÁö
  • activation gate
    °³¹æ °ü¹®(ËÒÛÁμڦ)
  • activation process
    Ȱ¼ºÈ­°úÁ¤.
  • activation, polyclonal
    ´Ù¼¼Æ÷±ºÈ°¼º, ¿©·¯¹«¸®È°¼º
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • heat of activation
    Ȱ¼ºÈ­¿­(üÀàõûýæð)
  • photochemical activation
    ±¤È°¼ºÈ­(Ë´Ì· ËÛÌ´).
  • plasmin activation inhibitor
    Çö󽺹ÎȰ¼ºÈ­¾ïÁ¦Á¦(¡­üÀàõûùåäð¤ð¥)
  • polyclonal B cell activation
    B¼¼Æ÷ ´Ù(¼ö)Ŭ·ÐȰ¼º, B¼¼Æ÷ ¿©·¯¹«¸®È°¼º
  • polyclonal activation
    ´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
  • AHF=£¾antihemophilic factor
    Ç×Ç÷¿ìÀÎÀÚ.
  • B cell differentiation factor (BCDF)
    B¼¼Æ÷ ºÐÈ­À¯¹ßÀÎÀÚ
  • B cell growth factor
    B ¼¼Æ÷¼ºÀåÀÎÀÚ
  • B cell growth factor (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
  • B cell stimulating factor (BSF)
    B¼¼Æ÷ ÀÚ±ØÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • macrophage migration inhibitory factor
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ.
  • activation
    Ȱ¼ºÈ­
  • activation
    Ȱ¼ºÈ­(üÀàõûù).
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • activation detector
    Ȱ¼ºÈ­ ŽÁö±â
  • activation energy
    Ȱ¼ºÈ­¿¡³ÊÁö
  • activation gate
    °³¹æ °ü¹®(ËÒÛÁμڦ)
  • activation process
    Ȱ¼ºÈ­°úÁ¤.
  • activation, polyclonal
    ´Ù¼¼Æ÷±ºÈ°¼º, ¿©·¯¹«¸®È°¼º
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • c3, activation
    C3, Ȱ¼º (¡­üÀàõ)
  • complement activation
    º¸Ã¼È°¼ºÀÛ¿ë(¡­üÀàõíÂéÄ), º¸Ã¼È°¼ºÈ­.
  • complement activation
    º¸Ã¼È°¼ºÀÛ¿ë
  • energy of activation
    Ȱ¼ºÈ­¿¡³ÊÁö.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reciprocal activation
    »óº¸ Ȱ¼ºÈ­(ßÓÜÍüÀàõûù)
  • upstream activation sites
    À­ÂÊ È°¼ºÈ­(üÀàõûù)ÀÚ¸®
  • acetate-replacing factor
    ¾Æ¼¼Æ®»ê(ß«)ġȯ ÀÎÀÚ(öÇüµì×í­)
  • achromotrichia factor
    ¸ð¹ß»ö¼Ò°áÇÌÀÎÀÚ (Ù¾Û¥ßäáÈÌÀù¹ì×í­)
  • angiogenic factor
    Ç÷°üÇü¼ºÀÎÀÚ(úìηû¡à÷ì×í­)
  • animal protein factor
    µ¿¹°´Ü¹éÁúÀÎÀÚ(ÔÑÚªÓ±ÛÜòõì×í­)
  • anti-egg-white injury factor
    Ç׳­¹é ¼Õ»óÀÎÀÚ(ù÷ÑëÛÜáßß¿ì×í­)
  • anti-fatty-liver-factor
    Ç×Áö¹æ°£ÀÎÀÚ(ù÷ò·Û¸ÊÜì×í­)
  • anti-gray-hair factor
    Ç×¹é¸ð¹ß ÀÎÀÚ(ù÷ÛÜÙ¾Û¥ì×í­)
  • antiacrodynia factor
    Ç×Áö´Üµ¿Åë ÀÎÀÚ(ù÷ò¶Ó®ÔÙ÷Ôì×í­)
  • antianemia factor
    Ç׺óÇ÷ÀÎÀÚ(ù÷Þ¸úìì×í­)
  • antiberiberi factor
    Ç×°¢±âÀÎÀÚ(ù÷ÊÅѨì×í­)
  • antiblack-tongue factor
    Ç×Èæ¼³ÀÎÀÚ(ù÷ýÙàßì×í­)
  • antihemophilic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ(ù÷úìéÒÜ»ì×í­)
  • antihemophilic factor B
    Ç×Ç÷¿ìº´ÀÎÀÚ (ù÷úìéÒÜ»ì×í­) B
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
PF pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid...
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GM-CSF Granulocyte Macrophage Colony Stimulating Factor
GM-CSF Granulocyte macrophage colony stimulator factor
GM-CSFr Granulocyte-macrophage colony-stimulating factor receptor
hGM CSF Human granulocyte-macrophage colony stimulating factor
hM-CSF Human macrophage colony-stimulating factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • polyclonal activation
    ´Ù¼ö Ŭ·Ð Ȱ¼º
  • receptor activation
    ¼ö¿ëü Ȱ¼ºÈ­, ¼ö¿ë±â Ȱ¼ºÈ­
  • secondary activation
    ÀÌÂ÷Àû Ȱ¼º
  • sympathetic activation
    ±³°¨½Å°æ°è Ȱ¼º
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • accessory food factor
    ¿µ¾ç º¸Á¶ ÀÎÀÚ
    F.G Ho
  • air kerma calibration factor
    °ø±â Ä¿¸¶ ÃøÁ¤ °è¼ö, ´«±Ý ¸ÂÃã °è¼ö
  • alveolar dilution factor
    ÆóÆ÷ Èñ¼® ÀÎÀÚ
  • angiogenesis factor
    Ç÷°ü Çü¼º ÀÎÀÚ
    ½Å»ý Ç÷°ü Áõ½ÄÀ» À¯µµÇÏ´Â ¹°Áú·Î¼­, Á¾¾çÀ̳ª ¸Á¸· °°Àº ½ÅÁø´ë»ç·®ÀÌ Å« Á¶Á÷¿¡¼­ ¹ß°ßµÈ´Ù. ÀÌ ÀÎÀÚ´Â »óóÀÇ °¡ÀåÀÚ¸®³ª Ç¥¸é¿¡ ÀÖ´Â Àú»ê¼Ò »óÅÂÀÇ ´ë½Ä¼¼Æ÷¿¡¼­ ºÐºñµÇ¸ç, »óó Ä¡À¯ °úÁ¤¿¡¼­ Ç÷°ü ÀçÇü¼ºÀ» À¯µµÇÑ´Ù.
  • anisotropy factor
    ºñµî¹æ¼º °è¼ö
  • antiangiogenesis factor
    Ç×Ç÷°ü»ý¼º ÀÎÀÚ
    Harvard ´ëÇп¡¼­ ¿¬±¸µÈ °ÍÀε¥ ¿¬°ñ¿¡´Â ¸ð¼¼Ç÷°üÀÌ Ä§ÅõµÇÁö ¾Ê´Â Çö»óÀ» °üÂûÇÏ°í ¾Ï Á¶Á÷¿¡ ¿¬°ñÁ¶Á÷¿¡¼­ À¯·¡µÈ antiangiogenesis factor¶ó´Â °ÍÀ» »ç¿ëÇÏ¿© ¾Ï Á¶Á÷ÀÇ ¼èÅ𸦠ÃÊ·¡ÇÏ¿´´Ù.
  • antihemophilic factor
    Ç×Ç÷¿ìº´ ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰 ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
macrophage migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
macrophage migration-inhibitory factors Proteins released by sensitised lymphocytes and possibly other cells that inhibit the migration of macrophages away from the release site. The structure and chemical properties may vary with the species and type of releasing cell.
(12 Dec 1998)
chemotactic factors, macrophage Cytotaxins liberated from normal or invading cells that specifically attract macrophages. They may be lymphokines, products of antigen, antibody and complement interactions or other.
(12 Dec 1998)
wandering macrophage <haematology> A macrophage that leaves the blood and migrates to infected tissue.
(09 Oct 1997)
Hansemann macrophage Large histiocytes with abundant cytoplasm that may contain Michaelis-Gutmann bodies and one or several nuclei; described in lesions of malacoplakia.
(05 Mar 2000)
inflammatory macrophage A macrophage found at sites of inflammation.
(05 Mar 2000)
fixed macrophage A relatively immotile macrophage found in connective tissue, lymph nodes, spleen, and bone marrow.
Synonym: resting wandering cell.
(05 Mar 2000)
free macrophage An actively motile macrophage typically found in sites of inflammation.
(05 Mar 2000)
activation <radiobiology> Activation occurs when a particle interacts with an atomic nucleus, shifting the nucleus into an unstable state, and causing it to become radioactive.
In fusion research, where deuterium-tritium is a common fuel mixture, the neutron released when (D + T) combine to form (4He + n) can activate the reactor structure. In this case the 4He is inert, the neutron sticks to another nucleus, and the neutron + nucleus reaction creates an actvation product. Sometimes called radioactivation.
See: activation product, activation analysis.
(09 Oct 1997)
activation analysis <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays.
Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many.
(09 Oct 1997)
activation energy <chemistry> The amount of energy (expressed in joules) that is needed to convert all the molecules in one mole of a reacting substance from a ground state to the transition state.
(06 May 1997)
activation product <radiobiology> The unstable nucleus formed when activation occurs. (See activation above.)
(09 Oct 1997)
amino acid activation The first step of protein synthesis, whereby an amino acid reacts with adenosine triphosphate in the presence of aminoacyl RNA synthetase to produce an amino acid adenylate, which provides the energy necessary for the attachment of the amino acid to a specific transfer RNA molecule.
(12 Dec 1998)
gene activation The process of activation of a gene so that it is expressed at a particular time. This process is crucial in growth and development.
(05 Mar 2000)
Gibbs energy of activation The Gibbs energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á